Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.

Alistair RD McLean; Chanida Indrasuta; Zay Soe Khant; Aung Kyaw Phyo; Sai Maung Maung; James Heaton; Hein Aung; Ye Aung; Kyaw Soe; Myo Maung Maung Swe; Lorenz von Seidlein; Ni Ni Tun; Kyaw Myo Tun; Nicholas PJ Day; Elizabeth A Ashley; Thaung Hlaing; Thar Tun Kyaw; Arjen M Dondorp; Mallika Imwong; Nicholas J White; Frank M Smithuis

Journal article

Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.

Alistair RD McLean, Chanida Indrasuta, Zay Soe Khant, Aung Kyaw Phyo, Sai Maung Maung, James Heaton, Hein Aung, Ye Aung, Kyaw Soe, Myo Maung Maung Swe, Lorenz von Seidlein, Ni Ni Tun, Kyaw Myo Tun, Nicholas PJ Day, Elizabeth A Ashley, Thaung Hlaing, Thar Tun Kyaw, Arjen M Dondorp, Mallika Imwong, Nicholas J White Show all

Lancet Infect Dis | Published : 2021

DOI: 10.1016/S1473-3099(20)30997-X

Abstract

BACKGROUND: To contain multidrug-resistant Plasmodium falciparum, malaria elimination in the Greater Mekong subregion needs to be accelerated while current antimalarials remain effective. We evaluated the safety, effectiveness, and potential resistance selection of dihydroartemisinin-piperaquine mass drug administration (MDA) in a region with artemisinin resistance in Myanmar. METHODS: We did a cluster-randomised controlled trial in rural community clusters in Kayin (Karen) state in southeast Myanmar. Malaria prevalence was assessed using ultrasensitive quantitative PCR (uPCR) in villages that were operationally suitable for MDA (villages with community willingness, no other malaria control ..

View full abstract